Song, Z., Wang, H., Zhang, H., Zhao, K., Zhang, M., & Yang, F. (2016). Efficacy and safety of triple therapy with aprepitant, ondansetron, and prednisone for preventing nausea and vomiting induced by R-CEOP or CEOP chemotherapy regimen for non-Hodgkin lymphoma: A phase 2 open-label, randomized comparative trial. Leukemia and Lymphoma, 58, 816–821.
To compare the use of a three-drug antiemetic regimen to a two-drug antiemetic regimen in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with non-Hodgkin lymphoma receiving R-CEOP or CEOP, highly emetogenic regimens (HECs)
PHASE OF CARE: Active antitumor treatment
Prospective, open-label, randomized, comparative clinical trial
Complete response (CR) was defined as no emesis and no use of rescue medications.
CR rate was achieved significantly with the addition of aprepitant to a two-drug antiemetic in both the acute and delayed phases. There were significant differences related to no emesis between the groups but no differences in nausea. For patients taking aprepitant, CINV had less affect on quality of life throughout treatment.
For patients receiving R-CEOP or CEOP for non-Hodgkin lymphoma, a three-drug regimen was more effective in preventing CINV than a two-drug regimen and was generally well-tolerated.